// App-Quantinova.ai

EP503 : MOSUNETUZUMAB (MOSUN) MONOTHERAPY FOR ELDERLY/UNFIT PATIENTS (PTS) WITH FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) CONTINUES TO SHOW PROMISING SAFETY AND EFFICACY WITH DURABLE COMPLETE RESPONSES

Researchers

Presenter

  • Adam Olszewski

Principal Investigators

  • Abraham Avigdor

  • Sunil Babu

  • Itai Levi

  • Herbert Eradat

  • Uri Abadi

  • Houston Holmes

  • Matthew McKinney

  • Dariusz Woszczyk

  • Krzysztof Giannopoulos

  • Wojciech Jurczak

  • Ron McCord

  • Yuying Xie

  • Kati Sarouei

  • Naseer Qayum

  • Carol O'Hear

  • Gila Sellam

  • Netanel Horowitz

Medical Centers

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Soroka University Medical Center, Beer Sheva, Israel

  • University of California LA, Los Angeles, United States

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Tel-Aviv University, Tel Aviv, Israel.

  • Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Texas Oncology,Dallas, TX,Vereinigte Staaten

  • Rambam Health Care Campus, Haifa, Israel

  • Brown University, Providence, Rhode Island, United States

  • Duke Cancer Institute,Durham,United States

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Meir Medical Center, Kfar-Saba, Israel

  • University of Opole, Provincial Hospital,Opole,Poland

  • Medical University of Lublin, Lublin, Poland

  • Sheba Medical Center, Ramat-Gan, Ireland

  • Genentech Inc., San Francisco, United States

Locations

  • Switzerland

  • Israel

  • United States

  • Poland

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Vincristine

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT02500407

  • NCT03677154

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved